Land: Malta
Tungumál: enska
Heimild: Medicines Authority
carbamazepine 100 mg
Novartis Pharmaceuticals UK Limited
N03AF01
carbamazepine
syrup
Authorised
2006-07-31
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING TEGRETOL ® Keep this leaflet. You may need to read it again. This medicine has been prescribed only for you. Do not give it to anybody else or use it for any other illnesses. If you have any further questions, ask your doctor or pharmacist. IN THIS LEAFLET 1 What Tegretol ® is and what it is used for 2 Before you take Tegretol 3 How to take Tegretol 4 Possible side effects 5 Storing Tegretol 6 Further information TEGRETOL The name of your medicine is Tegretol. It contains the active ingredient carbamazepine. Tegretol also contains other ingredients which are: TABLETS: Colloidal anhydrous silica, microcrystalline cellulose, magnesium stearate and sodium carboxymethylcellulose. CR TABLETS: Microcrystalline cellulose, sodium carboxymethylcellulose, polyacrylate dispersion, hypromellose, talc, colloidal anhydrous silica, ethylcellulose aqueous dispersion, magnesium stearate, titanium dioxide, polyoxylhydrogenated castor oil, yellow iron oxide, red iron oxide. ORAL SUSPENSION: Macrogol stearate, saccharin sodium, hydroxyethylcellulose, dispersable cellulose, sorbitol, propylene glycol, methylparahydroxybenzoate, propylparahydroxybenzoate, sorbic acid, caramel aroma 52929 A, purified water. Tegretol is available in the following forms (All amounts are in milligrams – mg): TABLETS containing 200 mg carbamazepine. CR TABLETS (slow-release tablets, which can be divided) containing 200 mg or 400 mg carbamazepine. ORAL SUSPENSION: 5 mL (1 measure) contain 100 mg carbamazepine. MARKETING AUTHORISATION HOLDER Novartis Pharmaceuticals UK Limited Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR, England MANUFACTURER The tablets and CR Lestu allt skjalið
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT TEGRETOL ® 200mg tablets TEGRETOL ® CR 200mg modified-release film-coated tablets TEGRETOL ® CR 400mg modified-release film-coated tablets TEGRETOL ® 100mg/5ml oral suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: 5H-dibenzo[b,f]azepine-5-carboxamide (carbamazepine) TABLETS: 200 mg carbamazepine. CR TABLETS (modified-release film-coated tablets, divisible): 200 mg and 400 mg carbamazepine. ORAL SUSPENSION: 5 mL (= 1 measure) contain 100 mg carbamazepine. For a full list of excipients, see section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Tablets Modified-release film-coated tablets (CR tablets) Oral suspension 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Epilepsy - Complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalization. - Generalized tonic-clonic seizures. Mixed forms of seizures. Tegretol ® is suitable for both monotherapy and combination therapy. Tegretol is usually not effective in absences (petit mal) and myoclonic seizures (see section 4.4 Special warnings and precautions for use). Acute mania and maintenance treatment of bipolar affective disorders to prevent or attenuate recurrence. Alcohol-withdrawal syndrome. Idiopathic trigeminal neuralgia and trigeminal neuralgia due to multiple sclerosis (either typical or atypical). Idiopathic glossopharyngeal neuralgia. Painful diabetic neuropathy. Diabetes insipidus centralis. Polyuria and polydipsia of neurohormonal origin. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The table Lestu allt skjalið